Frank Corrigan, MD
Interventional Cardiology · Atlanta, GANPI 1932348885
Payments from drug & device makers
Across 558 payments — averaging $466.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$161K
- Heartflow, Inc.$58K
- Boston Scientific$26K
- Abbott$4K
- Edwards Lifesciences$4K
- Medtronic$3K
- plus $4K from 28 others
Across 1 payment — averaging $1275.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $161,404 |
| Heartflow, Inc. | 65 | $57,614 |
| Boston Scientific | 181 | $26,018 |
| Abbott | 80 | $4,073 |
| Edwards Lifesciences | 27 | $3,796 |
| Medtronic(2 entities) | 38 | $3,109 |
| Shockwave Medical, Inc | 22 | $875 |
| Amgen | 20 | $599 |
| Inari Medical, Inc. | 6 | $546 |
| Abiomed | 3 | $308 |
| Siemens Medical Solutions USA, Inc. | 2 | $175 |
| Boehringer Ingelheim | 10 | $170 |
| Merck | 10 | $168 |
| Novo Nordisk | 7 | $145 |
| E.r. Squibb & Sons, L.L.C. | 9 | $142 |
| Johnson & Johnson | 9 | $128 |
| W. L. Gore & Associates, Inc. | 3 | $94 |
| Pfizer | 5 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $85 |
| Imperative Care, Inc | 3 | $82 |
| Stryker | 1 | $79 |
| Penumbra, Inc. | 3 | $71 |
| AstraZeneca | 3 | $61 |
| Recor Medical Inc | 2 | $55 |
| Philips North America LLC | 1 | $53 |
| Bayer | 2 | $43 |
| Vital Connect, Inc | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $28 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Cordis US CORP. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$260,163 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Atlanta
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
- Wissam JaberAtlanta$981K
- George HanzelAtlanta$750K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.